Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro for $43.00 per share in cash without interest.
The specialty pharmacy business could be valued at more than $4 billion in a sale, per a Bloomberg report, which cited people familiar with the matter.
Labor challenges, the expansion of healthcare services, store-count rationalization and PBM reform are among the front-burner issues in the year ahead.
The Future of Pharmacy Care Coalition is urging the 118th Congress to Enact H.R. 1770 to protect Medicare beneficiaries from the harms of COVID-19, flu, RSV and other infectious diseases.
Febuxostat tablets are indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol.
